

Justus B Cohen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7759273/publications.pdf>

Version: 2024-02-01

69
papers

3,149
citations

136950

32
h-index

155660

55
g-index

70
all docs

70
docs citations

70
times ranked

2636
citing authors

#	ARTICLE	IF	CITATIONS
1	CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. <i>Scientific Reports</i> , 2015, 5, 11483.	3.3	270
2	Diversity of germ-line immunoglobulin VH genes. <i>Nature</i> , 1981, 292, 426-430.	27.8	153
3	Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications. <i>Gene Therapy</i> , 1998, 5, 1517-1530.	4.5	152
4	A point mutation in the last intron responsible for increased expression and transforming activity of the c-Ha-ras oncogene. <i>Nature</i> , 1988, 334, 119-124.	27.8	139
5	Organization and evolution of immunoglobulin VH gene subgroups.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1982, 79, 4405-4409.	7.1	123
6	"Retroposon" insertion into the cellular oncogene c-myc in canine transmissible venereal tumor.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1985, 82, 1054-1058.	7.1	118
7	Rearrangement of the oncogene c-mos in mouse myeloma NS1 and hybridomas. <i>Nature</i> , 1983, 306, 797-799.	27.8	113
8	Simple DNA sequences in homologous flanking regions near immunoglobulin VH genes: a role in gene interaction?. <i>Nucleic Acids Research</i> , 1982, 10, 3353-3370.	14.5	112
9	Expression of the H-ras proto-oncogene is controlled by alternative splicing. <i>Cell</i> , 1989, 58, 461-472.	28.9	105
10	Effective Treatment of Experimental Glioblastoma by HSV Vector-Mediated TNF α and HSV-tk Gene Transfer in Combination with Radiosurgery and Ganciclovir Administration. <i>Molecular Therapy</i> , 2000, 2, 114-120.	8.2	99
11	Effective Treatment of an Orthotopic Xenograft Model of Human Glioblastoma Using an EGFR-retargeted Oncolytic Herpes Simplex Virus. <i>Molecular Therapy</i> , 2013, 21, 561-569.	8.2	94
12	Connexin 43-Enhanced Suicide Gene Therapy Using Herpesviral Vectors. <i>Molecular Therapy</i> , 2000, 1, 71-81.	8.2	87
13	Herpes simplex virus vector-mediated dystrophin gene transfer and expression in MDX mouse skeletal muscle. <i>Journal of Gene Medicine</i> , 1999, 1, 280-289.	2.8	69
14	Use of miRNA Response Sequences to Block Off-target Replication and Increase the Safety of an Unattenuated, Glioblastoma-targeted Oncolytic HSV. <i>Molecular Therapy</i> , 2015, 23, 99-107.	8.2	69
15	Equine Herpesvirus 1 Enters Cells by Two Different Pathways, and Infection Requires the Activation of the Cellular Kinase ROCK1. <i>Journal of Virology</i> , 2007, 81, 10879-10889.	3.4	62
16	Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model. <i>Gene Therapy</i> , 2002, 9, 584-591.	4.5	60
17	Pseudotyping of Glycoprotein D-Deficient Herpes Simplex Virus Type 1 with Vesicular Stomatitis Virus Glycoprotein G Enables Mutant Virus Attachment and Entry. <i>Journal of Virology</i> , 2000, 74, 2481-2487.	3.4	55
18	Treatment of rat gliosarcoma brain tumors by HSV-based multigene therapy combined with radiosurgery. <i>Molecular Therapy</i> , 2003, 8, 530-542.	8.2	51

#	ARTICLE	IF	CITATIONS
19	Gene therapy for the treatment of chronic peripheral nervous system pain. <i>Neurobiology of Disease</i> , 2012, 48, 255-270.	4.4	51
20	Engineering HSV-1 Vectors for Gene Therapy. <i>Methods in Molecular Biology</i> , 2014, 1144, 63-79.	0.9	51
21	Herpes simplex viral-vector design for efficient transduction of nonneuronal cells without cytotoxicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1632-41.	7.1	51
22	A Double Mutation in Glycoprotein gB Compensates for Ineffective gD-Dependent Initiation of Herpes Simplex Virus Type 1 Infection. <i>Journal of Virology</i> , 2010, 84, 12200-12209.	3.4	48
23	HSV vector cytotoxicity is inversely correlated with effective TK/GCV suicide gene therapy of rat gliosarcoma. <i>Gene Therapy</i> , 2000, 7, 1483-1490.	4.5	46
24	Design and application of oncolytic HSV vectors for glioblastoma therapy. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 505-517.	2.8	46
25	Herpes Simplex Virus Targeting to the EGF Receptor by a gD-Specific Soluble Bridging Molecule. <i>Molecular Therapy</i> , 2005, 11, 617-626.	8.2	44
26	Soluble V Domain of Nectin-1/HveC Enables Entry of Herpes Simplex Virus Type 1 (HSV-1) into HSV-Resistant Cells by Binding to Viral Glycoprotein D. <i>Journal of Virology</i> , 2006, 80, 138-148.	3.4	43
27	Chk2 is required for HSV-1 ICP0-mediated G2/M arrest and enhancement of virus growth. <i>Virology</i> , 2008, 375, 13-23.	2.4	42
28	Herpesvirus-Mediated Systemic Delivery of Nerve Growth Factor. <i>Molecular Therapy</i> , 2001, 3, 61-69.	8.2	41
29	Suppression of mammalian 5' splice-site defects by U1 small nuclear RNAs from a distance.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994, 91, 10470-10474.	7.1	40
30	Ectopic matrix metalloproteinase-9 expression in human brain tumor cells enhances oncolytic HSV vector infection. <i>Gene Therapy</i> , 2010, 17, 1200-1205.	4.5	40
31	Herpes Simplex Virus Vectors for Gene Transfer to the Central Nervous System. <i>Diseases (Basel)</i> , 2014, 4, 1-14. <small>Tj ETQq1 1 0.784314 rgBT /Overlock 2.5 40</small>	2.5	40
32	Equine herpesvirus type 1 (EHV-1) utilizes microtubules, dynein, and ROCK1 to productively infect cells. <i>Veterinary Microbiology</i> , 2010, 141, 12-21.	1.9	35
33	Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models. <i>Journal of Gene Medicine</i> , 2005, 7, 638-648.	2.8	33
34	Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity. <i>Molecular Therapy - Oncolytics</i> , 2014, 1, 14010.	4.4	33
35	Polymorphism of germ-line immunoglobulin VH genes correlates with allotype and idiotype markers. <i>European Journal of Immunology</i> , 1981, 11, 1017-1020.	2.9	32
36	Generation of Herpesvirus Entry Mediator (HVEM)-Restricted Herpes Simplex Virus Type 1 Mutant Viruses: Resistance of HVEM-Expressing Cells and Identification of Mutations That Rescue Nectin-1 Recognition. <i>Journal of Virology</i> , 2009, 83, 2951-2961.	3.4	31

#	ARTICLE	IF	CITATIONS
37	Development of an oncolytic HSV vector fully retargeted specifically to cellular EpCAM for virus entry and cell-to-cell spread. <i>Gene Therapy</i> , 2016, 23, 479-488.	4.5	30
38	Cloning and sequence of the cDNA corresponding to the variable region of immunoglobulin heavy chain MPC11. <i>Nucleic Acids Research</i> , 1980, 8, 3591-3602.	14.5	27
39	Novel Mutations in gB and gH Circumvent the Requirement for Known gD Receptors in Herpes Simplex Virus 1 Entry and Cell-to-Cell Spread. <i>Journal of Virology</i> , 2013, 87, 1430-1442.	3.4	27
40	Engineered HSV vector achieves safe long-term transgene expression in the central nervous system. <i>Scientific Reports</i> , 2017, 7, 1507.	3.3	27
41	Phenotypic heterogeneity associated with the splicing mutation in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 4081-4088.	3.6	26
42	Combination gene therapy for glioblastoma involving herpes simplex virus vector-mediated codelivery of mutant β -galactosidase and HSV thymidine kinase. <i>Cancer Gene Therapy</i> , 2005, 12, 487-496.	4.6	25
43	Equine Herpesvirus 1 Utilizes a Novel Herpesvirus Entry Receptor. <i>Journal of Virology</i> , 2005, 79, 3169-3173.	3.4	25
44	Retargeting of herpes simplex virus (HSV) vectors. <i>Current Opinion in Virology</i> , 2016, 21, 93-101.	5.4	24
45	Genetic Studies Exposing the Splicing Events Involved in Herpes Simplex Virus Type 1 Latency-Associated Transcript Production during Lytic and Latent Infection. <i>Journal of Virology</i> , 1999, 73, 3866-3876.	3.4	23
46	Bispecific Adapter-Mediated Retargeting of a Receptor-Restricted HSV-1 Vector to CEA-Bearing Tumor Cells. <i>Molecular Therapy</i> , 2011, 19, 507-514.	8.2	20
47	A repetitive sequence element 3' of the human c-Ha-ras1 gene has enhancer activity. <i>Journal of Cellular Physiology</i> , 1987, 133, 75-81.	4.1	19
48	Moving toward a gene therapy for Huntington's disease. <i>Gene Therapy</i> , 2015, 22, 931-933.	4.5	17
49	Engineering HSV-1 Vectors for Gene Therapy. <i>Methods in Molecular Biology</i> , 2020, 2060, 73-90.	0.9	17
50	Oncolytic Herpes Simplex Virus Vectors Fully Retargeted to Tumor-Associated Antigens. <i>Current Cancer Drug Targets</i> , 2018, 18, 162-170.	1.6	16
51	Point Mutations in Retargeted gD Eliminate the Sensitivity of EGFR/EGFRvIII-Targeted HSV to Key Neutralizing Antibodies. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 16, 145-154.	4.1	15
52	Characterization of soluble glycoprotein D-mediated herpes simplex virus type 1 infection. <i>Virology</i> , 2007, 360, 477-491.	2.4	14
53	Deletion of the Virion Host Shut-off Gene Enhances Neuronal-Selective Transgene Expression from an HSV Vector Lacking Functional IE Genes. <i>Molecular Therapy - Methods and Clinical Development</i> , 2017, 6, 79-90.	4.1	14
54	Mechanism of HSV infection through soluble adapter-mediated virus bridging to the EGF receptor. <i>Virology</i> , 2011, 413, 12-18.	2.4	12

#	ARTICLE	IF	CITATIONS
55	Expression of HSV-1 receptors in EBV-associated lymphoproliferative disease determines susceptibility to oncolytic HSV. <i>Gene Therapy</i> , 2013, 20, 761-769.	4.5	12
56	Cellular Antisilencing Elements Support Transgene Expression from Herpes Simplex Virus Vectors in the Absence of Immediate Early Gene Expression. <i>Journal of Virology</i> , 2018, 92, .	3.4	12
57	A Herpes Simplex Virus Vector System for Expression of Complex Cellular cDNA Libraries. <i>Journal of Virology</i> , 2010, 84, 7360-7368.	3.4	11
58	Inhibition of Indoleamine-2,3-dioxygenase (IDO) in Glioblastoma Cells by Oncolytic Herpes Simplex Virus. <i>Advances in Virology</i> , 2012, 2012, 1-10.	1.1	10
59	An HSV-based library screen identifies PP1 β as a negative TRPV1 regulator with analgesic activity in models of pain. <i>Molecular Therapy - Methods and Clinical Development</i> , 2016, 3, 16040.	4.1	9
60	Syncytial Mutations Do Not Impair the Specificity of Entry and Spread of a Glycoprotein D Receptor-Retargeted Herpes Simplex Virus. <i>Journal of Virology</i> , 2016, 90, 11096-11105.	3.4	8
61	Oncolytic HSV Vectors and Anti-Tumor Immunity. <i>Current Issues in Molecular Biology</i> , 2021, 41, 381-468.	2.4	8
62	Generation of an Oncolytic Herpes Simplex Viral Vector Completely Retargeted to the GDNF Receptor GFR α 1 for Specific Infection of Breast Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8815.	4.1	7
63	Constitutive Expression of GATA4 Dramatically Increases the Cardiogenic Potential of D3 Mouse Embryonic Stem Cells. <i>Open Biotechnology Journal</i> , 2016, 10, 248-257.	1.2	7
64	Protocol Optimization for the Production of the Non-Cytotoxic γ 1NI5 HSV Vector Deficient in Expression of Immediately Early Genes. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 17, 612-621.	4.1	5
65	Evaluation of parameters for efficient purification and long-term storage of herpes simplex virus-based vectors. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 26, 132-143.	4.1	3
66	Treatment of glioblastoma with current oHSV variants reveals differences in efficacy and immune cell recruitment. <i>Molecular Therapy - Oncolytics</i> , 2021, 22, 444-453.	4.4	1
67	Cloning and sequence of the cDNA corresponding to the variable region of immunoglobulin heavy chain MPC11. <i>Nucleic Acids Research</i> , 1980, 8, 4839-4839.	14.5	0
68	Herpes Simplex Virus Vectors. , 2010, , 69-85.		0
69	Abstract PO089: Comparison of Two oHSV Vectors for the Treatment of Glioblastoma. , 2021, , .		0